CK Life Sciences Intl : Retirement of Executive Director and Appointment of Executive Director

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

RETIREMENT OF EXECUTIVE DIRECTOR

AND

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board of Directors (the "Board") of CK Life Sciences Int'l., (Holdings) Inc. (the "Company") announces that with effect from 15th November, 2018, Dr. Chu Kee Hung ("Dr.

Chu") has retired as an Executive Director and Chief Scientific Officer of the Company. Dr. Chu continues to serve in his capacity as a Vice President of the Company. The Board would like to express their sincere gratitude to Dr. Chu for his invaluable contributions to the Company during his tenure of office.

In accordance with the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), Dr. Chu has confirmed that he has no disagreement with the Board and that he is not aware of any matters relating to his retirement that need to be brought to the attention of the shareholders of the Company.

The Board further announces that Dr. Toh Kean Meng, Melvin ("Dr. Toh") has been appointed as an Executive Director and Chief Scientific Officer of the Company with effect from 15th

November, 2018.

Set out below is the biographical profile of Dr. Toh:

Dr. TOH Kean Meng, Melvin

Dr. Toh, aged 52, is Vice President and Chief Scientific Officer of the Company. Dr. Toh joined the Group in January 2008 and was previously Vice President, Pharmaceutical Development, of the Company. He holds Bachelor of Medicine and Bachelor of Surgery degrees from the National University of Singapore and a Master of Science degree in Epidemiology from the University of London. He is registered with the Singapore Medical Council and the General Medical Council, United Kingdom. Dr. Toh has over 25 years of experience in clinical medicine and pharmaceutical research and development, and has held various management and scientific positions in Asia and the United States. Prior to joining the Group, Dr. Toh was Director of Clinical Pharmacology in Oncology Development, directing a team of scientists working on the clinical development of new cancer drugs for a leading pharmaceutical firm in the United States.

Dr. Toh does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. He does not have any interest in shares of the Company within the meaning of Part XV of the Securities Futures Ordinance. Pursuant to the Company's Articles of Association, Dr. Toh will hold office until the next general meeting of the Company when he will be eligible for re-election. The term of Dr. Toh's service as an Executive Director of the Company is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the provisions of the Articles of Association of the Company. The Director's fee of Dr. Toh as an Executive Director of the Company under his appointment letter is HK$75,000 per annum. Such fee is subject to review from time to time and proration for any incomplete year of service. The emoluments of Directors are determined by reference to the Company's performance and profitability, as well as the prevailing market conditions.

Save as disclosed herein, there are no other matters concerning Dr. Toh that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

By Order of the Board

CK Life Sciences Int'l., (Holdings) Inc.

Eirene Yeung

Company Secretary

Hong Kong, 15th November, 2018

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Colin Stevens Russel (Independent Non-executive Director) and Mr. Kwan Kai Cheong (Independent Non-executive Director).